Oncology CME

Over 64,000 people develop and close 50,000 die each year of pancreatic cancer, and by 2030, pancreatic cancer is expected to surpass colorectal and breast cancer to become the second-leading cause of cancer death. Over 90% of whom have pancreatic ductal adenocarcinoma (PDAC), and while the 5-year survival rate for patients diagnosed with localized disease is over 44%, patients with locally advanced (LAPC) or metastatic disease have a median overall survival of 12 to 14 months. Symptoms associated with pancreatic cancer are not usually evident in the early stages of the disease and may be intermittent and nonspecific, and more than half of patients have advanced disease by the time they are diagnosed.